Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Anti-calmodulins and Tricyclic Adjuvants in Pain Therapy Block the TRPV1 Channel

  • Zoltán Oláh ,

    To whom correspondence should be addressed. E-mail: zolah@brc.hu

    Affiliations Institute of Biochemistry, Biological Research Center of the Hungarian Academy of Sciences, Szeged, Hungary, Acheuron Hungary Ltd., Szeged, Hungary, Acheuron Pharmaceuticals Inc., San Diego, California, United States of America

  • Katalin Jósvay,

    Affiliation Institute of Biochemistry, Biological Research Center of the Hungarian Academy of Sciences, Szeged, Hungary

  • László Pecze,

    Affiliation Institute of Biochemistry, Biological Research Center of the Hungarian Academy of Sciences, Szeged, Hungary

  • Tamás Letoha,

    Affiliations Department of Medical Chemistry, Faculty of General Medicine, University of Szeged, Szeged, Hungary, Acheuron Hungary Ltd., Szeged, Hungary

  • Norbert Babai,

    Affiliation Department of Experimental Zoology and Neurobiology, University of Pécs, Pécs, Hungary

  • Dénes Budai,

    Affiliation Department of Biology, Gyula Juh‡sz Faculty of Education, University of Szeged, Szeged, Hungary

  • Ferenc Ötvös,

    Affiliation Institute of Biochemistry, Biological Research Center of the Hungarian Academy of Sciences, Szeged, Hungary

  • Sándor Szalma,

    Affiliation Acheuron Pharmaceuticals Inc., San Diego, California, United States of America

  • Csaba Vizler

    Affiliation Institute of Biochemistry, Biological Research Center of the Hungarian Academy of Sciences, Szeged, Hungary

Anti-calmodulins and Tricyclic Adjuvants in Pain Therapy Block the TRPV1 Channel

  • Zoltán Oláh, 
  • Katalin Jósvay, 
  • László Pecze, 
  • Tamás Letoha, 
  • Norbert Babai, 
  • Dénes Budai, 
  • Ferenc Ötvös, 
  • Sándor Szalma, 
  • Csaba Vizler
PLOS
x

Viewed info

Cited info

Saved info

Discussed info

Questions or concerns about usage data? Please let us know.